asco@alo33:161339 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/asco@alo33/sourceid/161339","sourcedb":"asco@alo33","sourceid":"161339","text":" Background: Small cell lung cancer SCLC is a common lung cancer hich presents ith extensive stage disease at time of diagnosis in to-thirds of patients. For treatment of advanced disease, traditional platinum doublet chemotherapy induces response rates up to 80 percent but ith fe durable responses. CPI-613 is a novel anti-cancer agent that selectively inhibits the altered form of mitochondrial energy metabolism in tumor cells. Methods: We evaluated CPI-613 ith a single-arm, open-label phase II study in patients ith relapsed or refractory SCLC. CPI-613 as given at a dose of 3,000 mgm2 on days 1 and 4 of eeks 1-3 of 4 eek cycle. To cycles ere given to complete a treatment course prior to re-evaluation. The primary outcome as response rate as assessed by CT imaging using RECIST v1.1 criteria. Secondary outcomes ere progression-free survival PFS , overall survival OS , and toxicity. Telve patients ere accrued median age 57yo ho had previously received beteen 1 and 4 lines of chemotherapy median 1 for SCLC ith a treatment-free interval of less than 60 days in 9 of the 12 patients. They received a total of 16.3 cycles median 1.63 of therapy ith a median maximum CPI-613 dosage of 30,000 mgm2 range 9,000 to 36,000 . Results: No complete or partial responses ere seen. Ten patients 83 percent progressed as best response and 2 17 percent ere not evaluable for response. Median time to progression as 1.7 months range 0.7 to 1.8 months . Eleven patients 92 percent died ith median overall survival of 4.3 months range 1.2 to 18.2 months . The study as closed early due to lack of efficacy. Of note, three out of three patients ho progressed after CPI-613 and ere subsequently treated ith standard topotecan then demonstrated treatment response ith survival for 18.2,7.4, and 5.1 months. We conducted laboratory studies hich found synergy in-vitro for CPI-613 ith topotecan. Conclusions: Single agent CPI-613 had no efficacy in this study. Further study of CPI 613 in combination ith a topoisomerase inhibitor is arranted. Clinical trial information: lta href=http:clinicaltrials.govshoNCT01931787 NCT01931787,J Clin Oncol 34, 2016 suppl; abstr e20100 ,NCT01931787Publication Only Lung CancerNon-Small Cell Local-RegionalSmall CellOther Thoracic Cancers \n","tracks":[{"project":"ASCO_abstracts","denotations":[{"id":"T1","span":{"begin":14,"end":36},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":38,"end":42},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":56,"end":67},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":304,"end":307},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":422,"end":427},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":457,"end":460},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":548,"end":552},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":554,"end":557},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":1022,"end":1026},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":1186,"end":1189},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T16","span":{"begin":1678,"end":1681},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T18","span":{"begin":1882,"end":1885},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T20","span":{"begin":1931,"end":1934},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T22","span":{"begin":1987,"end":1990},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0008433"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0008433"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005138"},{"id":"A4","pred":"mondo_id","subj":"T3","obj":"0008903"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0007336"},{"id":"A6","pred":"mondo_id","subj":"T5","obj":"0019621"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0005070"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0007336"},{"id":"A9","pred":"mondo_id","subj":"T8","obj":"0019621"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"0008433"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"0007336"},{"id":"A12","pred":"mondo_id","subj":"T11","obj":"0019621"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"0008433"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"0007336"},{"id":"A15","pred":"mondo_id","subj":"T14","obj":"0019621"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"0007336"},{"id":"A17","pred":"mondo_id","subj":"T16","obj":"0019621"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"0007336"},{"id":"A19","pred":"mondo_id","subj":"T18","obj":"0019621"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"0007336"},{"id":"A21","pred":"mondo_id","subj":"T20","obj":"0019621"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"0007336"},{"id":"A23","pred":"mondo_id","subj":"T22","obj":"0019621"},{"subj":"T1","pred":"source","obj":"ASCO_abstracts"},{"subj":"T2","pred":"source","obj":"ASCO_abstracts"},{"subj":"T3","pred":"source","obj":"ASCO_abstracts"},{"subj":"T5","pred":"source","obj":"ASCO_abstracts"},{"subj":"T7","pred":"source","obj":"ASCO_abstracts"},{"subj":"T8","pred":"source","obj":"ASCO_abstracts"},{"subj":"T10","pred":"source","obj":"ASCO_abstracts"},{"subj":"T11","pred":"source","obj":"ASCO_abstracts"},{"subj":"T13","pred":"source","obj":"ASCO_abstracts"},{"subj":"T14","pred":"source","obj":"ASCO_abstracts"},{"subj":"T16","pred":"source","obj":"ASCO_abstracts"},{"subj":"T18","pred":"source","obj":"ASCO_abstracts"},{"subj":"T20","pred":"source","obj":"ASCO_abstracts"},{"subj":"T22","pred":"source","obj":"ASCO_abstracts"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"ASCO_abstracts","color":"#93ecd4","default":true}]}]}}